Skip to content

This is a 3-part study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis

This is a 3-part study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis. This Phase 3 trial in patients with Plaque Psoriasis is being sponsored by Coherus Biosciences, Inc. This study is ongoing, but not recruiting participants.

This is a 3-part study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis 2If you would like to find active studies please search for clinical trials. A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis. This is a 3-part study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis. This 3-part study will compare the efficacy and safety of adalimumab biosimilar CHS-1420 versus Humira in subjects with chronic plaque psoriasis. A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis. This is a 3-part study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.

This rheumatoid arthritis study is the second of two, large, Phase 3 confirmatory trials intended for inclusion in global marketing applications for CHS-0214. Results for the first Phase 3 study in patients with chronic plaque psoriasis were released in November 2015 and showed that this first study also met its primary endpoints. We are pleased that this second pivotal clinical study comparing CHS-0214 to Enbrel has met its primary endpoint, said Denny Lanfear, President and Chief Executive Officer of Coherus. CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products. Coherus and Baxalta Announce CHS-0214 (Investigational Etanercept Biosimilar) Met Primary Efficacy Endpoint in Phase 3 Rheumatoid Arthritis Clinical Study (RaPsODY). Results for the first Phase 3 study in patients with chronic plaque psoriasis were released in November 2015 and showed that this first study also met its primary endpoints. We are pleased that this second pivotal clinical study comparing CHS-0214 to Enbrel has met its primary endpoint, said Denny Lanfear, President and Chief Executive Officer of Coherus. CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products. Plaque psoriasis has a significant impact on a patient’s quality of life and self-perception, so early access to treatment is imperative. If approved, CHS-0214 would expand access of treatment options for patients with moderate-to-severe chronic plaque psoriasis. Results for the second Phase 3 study in patients with rheumatoid arthritis are expected in the first quarter of 2016. CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products.

A Double-blind, Randomized, Parallel-group, Active-control Study To Compare The Efficacy And Safety Of Chs-1420 Versus Humira In Subjects With Chronic Plaque Psoriasis

This is a 3-part study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis 3CALYPSO clinical study is a phase 3 study which is carried out to establish the efficacy, safety and pharmacokinetic equivalence of BCD-055 (adalimumab, manufactured by JSC BIOCAD, Russia) and Humira when used in patients with moderate to severe plaque psoriasis. MSB11022 in Moderate to Severe Chronic Plaque Psoriasis. This is a two part study comparing CHS-1420 to Humira in patients with chronic plaque PsO. Biosimilar medicines are not required to have comparative phase III clinical trial data for all the indications of the original product. Patients who completed the PLANETRA study were eligible for entry into an open label extension phase covering an additional period of 48 weeks 6. AS, PsA, ulcerative colitis, Crohn’s disease and chronic plaque psoriasis (ClinicalTrials. Adalimumab CHS-1420, RA, Phase I. UK launch 2018. A similar Phase 3 confirmatory study as already proved CHS-0214 efficacy in chronic plaque psoriasis. CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), Coherus has proved to be a leader in the global biosimilar marketplace. If approved, CHS-0214 has the potential to expand access and treatment options for patients with moderate-to-severe rheumatoid arthritis and other inflammatory diseases for which etanercept is indicated. Results for the first Phase 3 study in patients with chronic plaque psoriasis were released in November 2015 and showed that this first study also met its primary endpoints. CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products. A study of the treatment of patients with chronic kidney disease undergoing haemodialysis with biocomparable and originator erythropoietin in Mexico reported comparable efficacy (in terms of changes in haemoglobin levels) and safety 67. An adalimumab biosimilar (CHS-1420) from fledgling biotech company Coherus Biosciences was reported to have met the criteria for comparable pharmacokinetics in a clinical study in healthy subjects 71. ThinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Baxalta Incorporated

Long-term effect on rats of the dust-radiation factor combined with chronic?